Vernal Biosciences Launches Integrated Services for mRNA Medicines

MRNA and lipid nanoparticle manufacturing experts, Vernal Biosciences, have announced the launch of its integrated analytical and QC services for plasmid DNA, mRNA, and lipid nanoparticles, as commercial services for customers’ complex analytical requirements in mRNA medicine development.

Vernal aims to support drug developers in evaluating CQAs and expediting timelines, whilst maintaining high safety and efficacy standards without compromise. Their state-of-the-art facility in Colchester, Vermont, offers access to advanced analytical technologies, including HPLC, UPLC-MS, digital PCR and nanopore sequencing to customers looking to streamline the development process and minimize costs.

Vernal Biosciences, a leader in mRNA and lipid nanoparticle (LNP) manufacturing, announces that its analytical and quality control (QC) services for plasmid DNA, mRNA, and LNPs are now commercially available as part of its seamless mRNA platform. These integrated services are the result of extensive development and validation to address the industry’s complex analytical needs.

By leveraging its expertise in mRNA and LNPs, Vernal empowers drug developers to evaluate critical quality attributes (CQAs) of their mRNA medicines, ensuring speed to the clinic and confidence in quality—factors vital for the success of mRNA programs and positive patient outcomes.

“Vernal is committed to enhancing outcomes for drug developers and ultimately patients,” said Christian Cobaugh, Ph.D., CEO and Founder of Vernal Biosciences. “Our one-stop-shop offers essential insights into the quality attributes of mRNA and LNP formulations, ensuring that innovators can achieve safety and efficacy without compromise, regardless of their program’s stage. While developing qualification-ready analytical methods is complex, our analytical and QC services streamline this process and expedite the journey to the clinic, enabling our customers to focus on solving critical challenges in medicine.”

Housed in a state-of-the-art facility in Colchester, Vermont, Vernal’s analytical technologies include capillary gel electrophoresis, digital and quantitative PCR testing, nanopore sequencing, HPLC, HPLC-CAD, UPLC-MS, UV and fluorescence spectrophotometry, dynamic light scattering, cell biology for potency assays, and more. With access to these methods, drug developers can streamline their programs, minimize vendor management, and accelerate their path to market while significantly lowering costs.

For more, please find the original story source here.